biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain content posted by a third party or links to third party websites (the “content” or “third party content”). this content is provided solely for general informational purposes as a convenience to you and not as an endorsement by the company of the content. it does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. the company is not responsible for this content and does not make any representations as to the subject matter, accuracy, completeness or timeliness or the content. if you decide to access linked third party websites, you do so at your own risk. there is no warranty of any kind, express or implied, regarding the content, including without limitation any warranty of m
Company profile
Ticker
BLRX
Exchange
Website
CEO
Philip Serlin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BioLineRX, Ltd.
SEC CIK
BLRX stock data
Latest filings (excl ownership)
6-K
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
17 Apr 24
6-K
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
10 Apr 24
6-K
BioLineRx Announces $6 Million Registered Direct Offering
1 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
20-F/A
2023 FY
Annual report (foreign) (amended)
26 Mar 24
20-F
2023 FY
Annual report (foreign)
26 Mar 24
6-K
BioLineRx Reports 2023 Financial Results and Recent Corporate
26 Mar 24
6-K
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
4 Mar 24
6-K
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
28 Feb 24
6-K
Current report (foreign)
16 Feb 24
Transcripts
BLRX
Earnings call transcript
2022 Q3
15 Nov 22
BLRX
Earnings call transcript
2022 Q2
16 Aug 22
BLRX
Earnings call transcript
2022 Q1
11 May 22
BLRX
Earnings call transcript
2021 Q4
16 Mar 22
BLRX
Earnings call transcript
2021 Q2
18 Aug 21
BLRX
Earnings call transcript
2021 Q1
26 May 21
BLRX
Earnings call transcript
2020 Q4
23 Feb 21
BLRX
Earnings call transcript
2020 Q3
23 Nov 20
Latest ownership filings
SC 13D
Hong Seng Technology Ltd
26 Oct 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
NOVARTIS PHARMA AG
16 Feb 21
SC 13G/A
Altium Capital Management LP
12 Feb 21
SC 13G/A
Senvest Management, LLC
12 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
6 Jan 21
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
3 Nov 20
SC 13G
ARMISTICE CAPITAL, LLC
5 Jun 20
SC 13G
INTRACOASTAL CAPITAL, LLC
5 Jun 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
39.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 8 |
Closed positions | 5 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 2.46 bn |
Total shares | 31.43 mm |
Total puts | 107.20 k |
Total calls | 99.10 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 19.13 mm | $31.57 mm |
Biotechnology Value Fund L P | 5.95 mm | $11.78 mm |
Novartis Pharma | 5.00 mm | $12.60 mm |
Susquehanna International | 237.34 k | $431.95 mm |
Sabby Management | 210.00 k | $382.20 mm |
MS Morgan Stanley | 175.76 k | $319.89 mm |
LPL Financial | 113.71 k | $206.95 mm |
Atria Wealth Solutions | 110.37 k | $200.87 mm |
Citadel Advisors | 58.95 k | $107.30 mm |
Envestnet Asset Management | 58.14 k | $105.81 mm |
News
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
17 Apr 24
BioLineRx Announces $6M Registered Direct Offering Of 7.5M ADS And Warrants To Purchase Up To An Aggregate Of 7.5M ADSs, At A Combined Purchase Price Of $0.80 Per ADS And Accompanying Warrant
1 Apr 24
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
26 Mar 24
BioLine Rx Q4 EPS $(0.15) Beats $(0.22) Estimate, Sales $4.80M
26 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Mar 24
Press releases
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
17 Apr 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
4 Mar 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
28 Feb 24
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
16 Feb 24